Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as tipifarnib (R115777)
Tipifarnib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| tipifarnib (R115777) | DRUG | - |
Inclusion Criteria: * Refractory or relapsed Acute myeloid leukemia (AML) * Eastern Cooperative Oncology Group (ECOG) performance of 0-2 * any value of WBC * able to eat food and medication orally * females must use contraception and not be pregnant Exclusion Criteria: * .Not in another study wit...
Tipifarnib is an investigational small molecule being studied for the treatment of acute myeloid leukemia, also described as nonlymphocytic acute leukemia. It has been evaluated in patients with relapsed or refractory disease. It is not an approved therapy and remains in clinical development.
Tipifarnib is developed by Johnson & Johnson, which trades under the ticker JNJ. The company sponsored the clinical research evaluating the drug in acute myeloid leukemia.
Tipifarnib is in Phase 2 development. A single Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication.
Tipifarnib has been studied in one completed Phase 2 trial, NCT00354146, titled a study of farnesyl transferase inhibitor R115777 (tipifarnib) in patients with refractory or relapsed acute myeloid leukemia. The trial enrolled 252 patients aged 18 years and older and was uncontrolled.
Yes, tipifarnib is also known as R115777. The two names refer to the same investigational small molecule developed by Johnson & Johnson for acute myeloid leukemia.